[Echinocandins and the 2009 guidelines for treatment of candidiasis].
Candida is the most frequent cause of invasive fungal infections in humans that yield high levels of mortality and health-related costs. Several factors lead to the development of candidemia. The Infectious Diseases Society of America (IDSA) updated its guidelines for the management of candidiasis and proper use of antifungal agents in Candida infections. The echinocandins are novel antifungal 1,3-beta-glucan synthase inhibitors and are currently the first choice treatment for most Candida infections, with good responses to support its use.
Melo
Luis Henrique
LH
Faculdade de Medicina da Universidade de Joinville, and Setor de Doenças Infecciosas do Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil.
D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D054714:Echinocandins / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D017408:Guidelines as Topic; D006801:Humans; D009503:Neutropenia / Q000150:complications; D011704:Pyelonephritis / Q000209:etiology
D000935:Antifungal Agents; D054714:Echinocandins; D004791:Enzyme Inhibitors; D005964:Glucosyltransferases; C020570:1,3-beta-glucan synthase